{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T12:02:27Z","timestamp":1793275347375,"version":"4.5.0"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100007343","name":"Universit\u00e0 degli Studi di Brescia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007343","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytokine"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.cyto.2019.154884","type":"journal-article","created":{"date-parts":[[2019,10,26]],"date-time":"2019-10-26T05:01:52Z","timestamp":1572066112000},"page":"154884","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["The impact of integrase inhibitor-based regimens on markers of inflammation among HIV na\u00efve patients"],"prefix":"10.1016","volume":"126","author":[{"given":"Eugenia","family":"Quiros-Roldan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Castelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Bonito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marika","family":"Vezzoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4996-7995","authenticated-orcid":false,"given":"Stefano","family":"Calza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Biasiotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3902-3376","authenticated-orcid":false,"given":"Isabella","family":"Zanella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cyto.2019.154884_b0005","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/QAD.0000000000000545","article-title":"The effect of HAART-induced HIV suppression on circulating markers of inflammation and immune activation","volume":"29","author":"Wada","year":"2015","journal-title":"AIDS"},{"key":"10.1016\/j.cyto.2019.154884_b0010","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1086\/652749","article-title":"Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection","volume":"201","author":"Neuhaus","year":"2010","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.cyto.2019.154884_b0015","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1186\/s12967-017-1358-6","article-title":"The impact of antiretroviral therapy on iron homeostasis and inflammation markers in HIV-infected patients with mild anemia","volume":"15","author":"Quiros-Roldan","year":"2017","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.cyto.2019.154884_b0020","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1093\/infdis\/jix666","article-title":"Changes in Inflammation but not in T-cell activation precede non AIDS-defining events in a case-control study of patients on long-term antiretroviral therapy","volume":"218","author":"Angelidou","year":"2018","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.cyto.2019.154884_b0025","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/01.qai.0000437171.00504.41","article-title":"Associations of inflammatory markers with AIDS and non-AIDS clinical events after initiation of antiretroviral therapy: AIDS clinical trials group A5224s, a substudy of ACTG A5202","volume":"65","author":"McComsey","year":"2014","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.cyto.2019.154884_b0030","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1097\/QAD.0000000000000618","article-title":"Plasma levels of cytokines and chemokines and the risk of mortality in HIV-infected individuals: a case-control analysis nested in a large clinical trial","volume":"29","author":"French","year":"2015","journal-title":"AIDS"},{"key":"10.1016\/j.cyto.2019.154884_b0035","doi-asserted-by":"crossref","first-page":"61","DOI":"10.2174\/1570162X1401151102143222","article-title":"Changes in serum markers of inflammation and endothelial activation in HIV-infected antiretroviral naive patients starting a treatment with abacavir-lamivudine or tenofovir emtricitabine plus efavirenz","volume":"14","author":"Calza","year":"2016","journal-title":"Curr. HIV Res."},{"key":"10.1016\/j.cyto.2019.154884_b0040","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/infdis\/jiv004","article-title":"Differential reduction in monocyte activation and vascular inflammation with integrase inhibitor-based initial antiretroviral therapy among HIV-infected individuals","volume":"212","author":"Hileman","year":"2015","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.cyto.2019.154884_b0045","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1097\/QAD.0b013e328359f29c","article-title":"Changes in cardiovascular biomarkers in HIV-infected patients switching from ritonavir-boosted protease inhibitors to raltegravir","volume":"26","author":"Mart\u00ednez","year":"2012","journal-title":"AIDS"},{"key":"10.1016\/j.cyto.2019.154884_b0050","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1097\/QAD.0b013e328354f4fb","article-title":"Inflammation markers after randomization to abacavir\/lamivudine or tenofovir\/emtricitabine with efavirenz or atazanavir\/ritonavir","volume":"26","author":"McComsey","year":"2012","journal-title":"AIDS"},{"issue":"4","key":"10.1016\/j.cyto.2019.154884_b0055","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1006285","article-title":"Levels of HIV-1 persistence on antiretroviral therapy are not associated with markers of inflammation or activation","volume":"13","author":"Gandhi","year":"2017","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.cyto.2019.154884_b0060","doi-asserted-by":"crossref","first-page":"9838","DOI":"10.1073\/pnas.88.21.9838","article-title":"Lymphoid organs function as major reservoirs for human immunodeficiency virus","volume":"88","author":"Pantaleo","year":"1991","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.cyto.2019.154884_b0065","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s12977-016-0325-2","article-title":"HIV integration sites in latently infected cell lines: evidence of ongoing replication","volume":"14","author":"Symons","year":"2017","journal-title":"Retrovirology"},{"key":"10.1016\/j.cyto.2019.154884_b0070","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1002\/path.2276","article-title":"Immune activation and inflammation in HIV-1 infection: causes and consequences","volume":"214","author":"Appay","year":"2008","journal-title":"J. Pathol."},{"key":"10.1016\/j.cyto.2019.154884_b0075","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jcv.2017.03.018","article-title":"Total cellular HIV-1 DNA decreases after switching to raltegravir-based regimens in patients with suppressed HIV-1 RNA","volume":"91","author":"Rossetti","year":"2017","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.cyto.2019.154884_b0080","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/QAD.0b013e32834e8955","article-title":"Effect of raltegravir intensification on HIV proviral DNA in the blood and gut mucosa of men on long-term therapy: a randomized controlled trial","volume":"26","author":"Chege","year":"2012","journal-title":"AIDS"},{"key":"10.1016\/j.cyto.2019.154884_b0085","doi-asserted-by":"crossref","first-page":"355","DOI":"10.3851\/IMP1917","article-title":"Treatment intensification with raltegravir in subjects with sustained HIV-1 viraemia suppression: a randomized 48-week study","volume":"17","author":"Llibre","year":"2012","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.cyto.2019.154884_b0090","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/nm.2111","article-title":"HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects","volume":"16","author":"Buz\u00f3n","year":"2010","journal-title":"Nat. Med."},{"key":"10.1016\/j.cyto.2019.154884_b0095","article-title":"Switching from a protease inhibitor\u2013based regimen to a dolutegravir-based regimen: a randomized clinical trial to determine the effect on peripheral blood and ileum biopsies from ART-suppressed HIV-infected individuals","author":"Moron-Lopez","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.cyto.2019.154884_b0100","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1093\/cid\/civ327","article-title":"Changes in inflammation and immune activation with atazanavir-, raltegravir-, darunavir-based initial antiviral therapy: ACTG 5260s","volume":"61","author":"Kelesidis","year":"2015","journal-title":"Clin. Infect. Dis."},{"issue":"2","key":"10.1016\/j.cyto.2019.154884_b0105","article-title":"Cohort Profile: standardized management of antiretroviral therapy cohort (MASTER Cohort)","volume":"46","author":"Torti","year":"2015","journal-title":"Int. J. Epidemiol."},{"key":"10.1016\/j.cyto.2019.154884_b0110","unstructured":"EACS Guidelines version 9.1, October 2018. http:\/\/www.eacsociety.org\/files\/2018_guidelines-9.1."},{"key":"10.1016\/j.cyto.2019.154884_b0115","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/S1473-3099(13)70257-3","article-title":"Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial","volume":"13","author":"Raffi","year":"2013","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.cyto.2019.154884_b0120","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1093\/jac\/dky497","article-title":"Integrase strand transfer inhibitors and neuropsychiatric adverse events in a large prospective cohort","volume":"74","author":"Cuzin","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.cyto.2019.154884_b0125","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/bcpt.12828","article-title":"Clinical experience with the integrase inhibitors dolutegravir and elvitegravir in Hiv-infected patients: efficacy, safety and tolerance","volume":"121","author":"Cid-Silva","year":"2017","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"10.1016\/j.cyto.2019.154884_b0130","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1111\/hiv.12257","article-title":"Soluble biomarkers of immune activation and inflammation in HIV infection: impact of 2 years of effective first-line combination antiretroviral therapy","volume":"16","author":"Hattab","year":"2015","journal-title":"HIV Med."},{"key":"10.1016\/j.cyto.2019.154884_b0135","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1086\/605890","article-title":"Serum immune activation markers are persistently increased in patients with HIV infection after 6 years of antiretroviral therapy despite suppression of viral replication and reconstitution of CD4 + T cells","volume":"200","author":"French","year":"2009","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.cyto.2019.154884_b0140","doi-asserted-by":"crossref","first-page":"4321","DOI":"10.1182\/blood-2012-11-465625","article-title":"Interleukin-7 promotes HIV persistence during antiretroviral therapy","volume":"121","author":"Vandergeeten","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.cyto.2019.154884_b0145","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/QAI.0b013e31828ace69","article-title":"Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir\/emtricitabine in treatment-naive HIV-1\u2013infected patients: final 5-year results from STARTMRK","volume":"63","author":"Rockstroh","year":"2013","journal-title":"JAIDS J Acquir Immune Defic Syndr."},{"key":"10.1016\/j.cyto.2019.154884_b0150","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1056\/NEJMoa1215541","article-title":"Dolutegravir plus abacavir\u2013lamivudine for the treatment of HIV-1 infection","volume":"369","author":"Walmsley","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cyto.2019.154884_b0155","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1172\/JCI200522574","article-title":"IL-7 is a potent and proviral strain-specific inducer of latent HIV-1 cellular reservoirs of infected individuals on virally suppressive HAART","volume":"115","author":"Wang","year":"2005","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.cyto.2019.154884_b0160","doi-asserted-by":"crossref","first-page":"13077","DOI":"10.1128\/JVI.76.24.13077-13082.2002","article-title":"Interleukin-7 induces expression of latent human immunodeficiency virus type 1 with minimal effects on T-cell phenotype","volume":"76","author":"Scripture-Adams","year":"2002","journal-title":"J. Virol."},{"key":"10.1016\/j.cyto.2019.154884_b0165","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/QAD.0000000000000894","article-title":"Treatment intensification followed by interleukin-7 reactivates HIV without reducing total HIV DNA: a randomized trial","volume":"30","author":"Katlama","year":"2016","journal-title":"AIDS"},{"key":"10.1016\/j.cyto.2019.154884_b0170","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/infdis\/jiv004","article-title":"Differential reduction in monocyte activation and vascular inflammation with integrase inhibitor - based initial antiretroviral therapy among HIV-infected individuals","volume":"212","author":"Hileman","year":"2015","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.cyto.2019.154884_b0175","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.antiviral.2016.05.013","article-title":"Impact of elvitegravir on human adipocytes: alterations in differentiation, gene expression and release of adipokines and cytokines","volume":"132","author":"Moure","year":"2016","journal-title":"Antiviral Res."},{"issue":"1","key":"10.1016\/j.cyto.2019.154884_b0180","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3851\/IMP3091","article-title":"Treatment of HIV infection with a raltegravir-based regimen increases LDL levels, but improves HDL cholesterol efflux capacity","volume":"22","author":"Funderburg","year":"2016","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.cyto.2019.154884_b0185","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1089\/aid.2014.0239","article-title":"Characterization of lipid composition and high-density lipoprotein function in HIV-infected individuals on stable antiretroviral regimens","volume":"31","author":"Munger","year":"2015","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"10.1016\/j.cyto.2019.154884_b0190","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1097\/COH.0000000000000020","article-title":"Can early therapy reduce inflammation?","volume":"9","author":"Sandler","year":"2014","journal-title":"Curr. Opin. HIV AIDS"},{"issue":"7","key":"10.1016\/j.cyto.2019.154884_b0195","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1097\/QAD.0000000000000158","article-title":"Soluble CD14 is independently associated with coronary calcification and extent of subclinical vascular disease in treated HIV infection","volume":"28","author":"Longenecker","year":"2014","journal-title":"AIDS"},{"key":"10.1016\/j.cyto.2019.154884_b0200","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1097\/QAD.0000000000000145","article-title":"Immunologic predictors of coronary artery calcium progression in a contemporary HIV cohort","volume":"28","author":"Baker","year":"2014","journal-title":"AIDS"},{"issue":"6","key":"10.1016\/j.cyto.2019.154884_b0205","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2017.237","article-title":"HIV integrase inhibitor, Elvitegravir, impairs RAG functions and inhibits V(D)J recombination","volume":"8","author":"Nishana","year":"2017","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.cyto.2019.154884_b0210","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.tiv.2016.12.002","article-title":"The consequence of regional gradients of P-gp and CYP3A4 for drug-drug interactions by P-gp inhibitors and the P-gp\/CYP3A4 interplay in the human intestine ex vivo","volume":"40","author":"Li","year":"2017","journal-title":"Toxicol. Vitr."},{"key":"10.1016\/j.cyto.2019.154884_b0215","unstructured":"C.V. Fletcher, A. Thorkelson, L. Winchester, T. Mykris, J. Weinhold, K. Campbell, et al., Comparative lymphoid tissue pharmacokinetics (pk) of integrase inhibitors (insti), in: Abstracts of the 25th Conference on Retroviruses Opportunistic Infection (CROI), Boston, MA, 2018 (Abstract 27)."},{"key":"10.1016\/j.cyto.2019.154884_b0220","doi-asserted-by":"crossref","first-page":"141","DOI":"10.3851\/IMP2681","article-title":"Comparison of cardiovascular disease risk markers in HIV infected patients receiving abacavir and tenofovir: the nucleoside inflammation, coagulation and endothelial function (NICE) study","volume":"19","author":"Wohl","year":"2014","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.cyto.2019.154884_b0225","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/1471-2334-14-122","article-title":"Comparative impact of antiretroviral drugs on markers of inflammation and immune activation during the first two years of effective therapy for HIV-1 infection: an observational study","volume":"14","author":"Hattab","year":"2014","journal-title":"BMC Infect. Dis."}],"container-title":["Cytokine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043466619303138?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043466619303138?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T20:55:41Z","timestamp":1760907341000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043466619303138"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":45,"alternative-id":["S1043466619303138"],"URL":"https:\/\/doi.org\/10.1016\/j.cyto.2019.154884","relation":{},"ISSN":["1043-4666"],"issn-type":[{"value":"1043-4666","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The impact of integrase inhibitor-based regimens on markers of inflammation among HIV na\u00efve patients","name":"articletitle","label":"Article Title"},{"value":"Cytokine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cyto.2019.154884","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"154884"}}